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ABSTRACT 
The objective of the present work was to prepare intranasal solid lipid nanoparticles (SLN) of mometasone furoate. Mometasone furoate is BCS 
class II drug having low aqueous solubility and highly sensitive to hepatic metabolism. Mometasone furoate loaded nanoparticles were 
prepared by high pressure homogenization technique. The preformulation studied was conducted by studying various selection criteria. Lipid 
was chosen on the basis of maximum solubility of the drug in lipid.  Glyceryl monostearate was selected as the lipid phase which showed 
maximum drug solubility than other lipids. Selection of surfactant, homogenization pressure and no. of homogenization cycle was done on the 
basis of minimum particle size and maximum % entrapment efficiency. These results showed high entrapment efficiency and minimum particle 
size. 
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INTRODUCTION:  
Mometasone furoate is categorized as a potent 
vasoconstrictor, anti-inflammatory drug, selected for nasal 
solid lipid nanoparticle formulation. This is a corticosteroid 
hormone receptor agonist having anti-allergic and anti-
inflammatory activity [1, 2].  
The oral bioavailability of mometasone furoate is close to 
zero. Studies have reported that any amount of mometasone 
furoate that is ingested and absorbed undergoes extensive 
metabolism to multiple metabolites. Nasal absorption of the 
drug into the systemic circulation takes place very 
effectively. The recommended nasal dose of mometasone 
furoate is 400 mcg per day for an adult. It has the half-life of 
about 5.8 hrs with 99% plasma protein binding. The nasal 
administration of mometasone furoate SLN would be 
effective and it could be highly acceptable option for drug 
delivery [3-5]. 
Solid lipid nanoparticles can improve systemic drug delivery, 
since they are able to protect the encapsulated drug from 
biological or chemical degradation and from extracellular 
transport by P-gp efflux proteins [6]. Solid lipid nanoparticles 
are considered to be among the most effective lipid-based 
colloidal vehicles. They are constituted by a solid lipid matrix 
surrounded by a layer of surfactants in an aqueous 
dispersion [7]. 
MATERIALS AND METHODS: 
Materials:   
Mometasone was gifted by Glenmark Phamrmaceuticals, 
Baddi, HP, India IMWITOR® 900 K (glyceryl monostearate) 
gifted by IOI Oleo Gmbh , Germany. Tween 80 was obtained 
from  Loba Chemie, Mumbai, India. Benzalkonium chloride 
was obtained from Molychem, Mumbai, India.                                                                                                                                                       
Methods:  
Selection of excipients and their levels:                                                                                              
Selection of lipid: 
Selection of lipid depends on the basis of solubility of drug in 
lipid and also on the melting point of lipid. For the 
preparation of solid lipid nanoparticles loaded with 
mometasone furate, drug should be completely soluble in 
lipid. Various lipids such as Dynasan 118 , Emulsire 61, 
Imwitor 900 k (GMS), Precirol ATO 5, Compritol 888 ATO, 
Gelucire, and Stearic acid were used to study the solubility of 
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drug. The total amount of lipid added to get a clear solution 
was recorded. 
Selection of surfactant and its concentration: 
Different surfactant were tried to prepare SLN. SLN are 
colloidal system of nanoparticles made up of solid lipid as 
matrix medium which is stabilize in aqueous media by 
surfactant. For preparation of SLN various surfactants used 
Such as Tween 80, Tween 20, Poloxamer 188 was used to 
observed particle size and entrapment efficiency. Surfactant 
concentration also influences particle size of formulation.  
Selection of homogenization cycle and pressure:  
Number of homogenization cycles and homogenization 
pressure were screened to get minimum particle size and 
maximum entrapment efficiency. Prepared pre-emulsion was 
passed into homogenization. 
Preparation of SLN: 
High pressure homogenization Method:    
SLN formulation was prepared using HPH (high pressure 
homogenization) method.  In this method, glyceryl 
monostearte was melted 5 to 10 ºC above the melting point 
of lipid.  Mometasone furoate was dissolved in lipid under 
continuous stirring. Later surfactant water phase was added 
slowly and heated the same as drug lipid phase. 
Benzalkonium chloride was added to this pre-dispersion as a 
preservative. Pre-emulsion was obtained under stirring at 
high speed up to 1500 rpm. This pre-emulsion was passed 
through high pressure homogenizer. The obtained o/w 
dispersion formed was immediately cooled down to room 
temperature. Mometasone furoate loaded SLN dispersion 
was subjected to characterization.  
RESULTS AND DISCUSSION:  
Selection of lipid:  
The maximum solubility of mometasone furoate was 
obtained in glyceryl monostearate (Figure 1). Greater 
solubility of the drug in lipid helps in formulation of matrix 
type of SLN. Maximum solubility of drug into the lipid phase 
is required for producing formulation with high drug load 
thus delivering maximum amount of drug to the site of 
action. 2 to 5 % lipid showed high viscosity and stability. Use 
of high concentration of lipid produced more viscous pre-
emulsion and produced higher particle size. Lower 
concentration of lipid could not dissolve mometasone 
furoate.
 
 
Figure 1: solubility of mometasone furoate in different lipid. 
 
Selection of surfactant: 
Different surfactants were screened to prepare SLN and the 
resultant particle size was observed in (table 1). 
Formulations containing Tween 20, Poloxamer 188 showed 
high particle size than Tween 80 and also gives low 
entrapment efficiency. Tween 80 resulted in particle size 218 
±1.7 and entrapment efficiency 72 % and hence it was 
selected as surfactant. 
 
Table 1: Effect of surfactant on particle size and entrapment efficiency 
Sr. no. Type of surfactant Particle size 
(nm) 
Entrapment efficiency 
(%) 
1               Poloxamer 188 480±5 65 
2   Tween 80 218±4 72 
3 Tween 20 319±3 64 
n=3 
Selection of surfactant concentration: 
The surfactant concentration affects the particle size of SLN 
by causing the stabilization of the particles. It was observed 
that 0.5% concentration gives high particle size of 312 nm 
and when the concentration of surfactant was increased, 
there was a decreased in particle size (table 2). Surfactant 
concentration 4% and 5% reduced entrapment efficiency to 
41%. Higher concentration of surfactant solubilizes drug in 
the micelles in the aqueous phase, leading to reduced 
entrapment efficiency. 
Madgulkar et al                                                                                                      Journal of Drug Delivery & Therapeutics. 2019; 9(4):526-528 
  
ISSN: 2250-1177                                                                                  [528]                                                                                 CODEN (USA): JDDTAO 
Table 2: Effect of surfactant concentration particle size and entrapment efficiency 
Sr. no. Surfactant 
Concentrations (%) 
Particle size 
 (nm) 
Entrapment efficiency (%) 
1 0.5 312±3 38 
2 1 272±4 48 
 3 2 240±6 64 
 4 3 116±3 70 
           5 4 110±2 51 
           6 5 112±1 41 
n=3 
Selection of homogenization cycles: 
It was observed that as the no. of homogenization cycle 
increased, particle size was decreased (table 3). An increase 
in 9 to 12 the homogenization cycles resulted in increased 
particle size. This might be due to the high kinetic energy of 
small particles that showed aggregation of particles. It was 
observed that entrapment efficiency was not significantly 
affected by the homogenization cycles. After 5 
homogenization cycles entrapment efficiency was reduced. 
Increasing number of homogenization cycles also decreased 
entrapment efficiency due to the aggregation of particles.
 
Table 3: Effect of surfactant on particle size and entrapment efficiency 
Sr. no. No. of homogenization cycles Particle size 
 (nm) 
Entrapment efficiency 
(%) 
1 1 348±3 80 
2 3 240±2 75 
3 5 180±4 74 
4 7 148±4 71 
5 9 212±3 68 
6 10 388±7 66 
7 12 412±2 61 
                                                                                            n=3  
Selection of homogenization pressure: 
It was observed that applied homogenization pressure 
highly influences the particle size. When the applied 
homogenization pressure was increased from 200-1000 bar, 
particle size slowly decreased from 400nm to 138 nm (table 
4). Increasing the homogenization pressure leads to an 
increase of particle size due to coalescence. This occurs 
because of the high kinetic energy of the particles [8]. 
Table 4: Effect of homogenization pressure on particle 
size 
Sr. 
no. 
homogenization pressure 
 (bar) 
Particle size 
 (nm) 
1 200 410±4 
2 400 311±2 
3 600 157±1 
4 700 140±5 
5 1000 138±3 
6 1200 219±6 
 
CONCLUSION:  
Different formulations were developed and its particle size 
and % entrapment efficiency were studied.  
As a result of the study the selection of lipid was done on the 
basis of maximum solubility of the drug in lipid. Glyceryl 
monostearate was selected as the lipid phase for 
mometasone furoate SLN preparation as it showed 
maximum drug solubility than other lipids. Selection of 
surfactant, homogenization pressure and no. of 
homogenization cycle was done on the basis of minimum 
particle size and maximum % entrapment efficiency. In the 
formulation study screening different surfactants were tried 
to prepare SLN. Tween 80 resulted in minimum particle size 
and maximum % entrapment efficiency and hence this was 
selected as a surfactant. 
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